PUBLISHER: DelveInsight | PRODUCT CODE: 1105508
PUBLISHER: DelveInsight | PRODUCT CODE: 1105508
DelveInsight's, ''Common Warts - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Common Warts Understanding
Warts are benign lesions that occur in the mucosa and skin. Warts are caused by the human papillomavirus (HPV), with over 100 types of HPV identified. HPV may occur at any site. The primary manifestations of HPV infection include common warts, genital warts, flat warts, deep palmoplantar warts (Myrmecia), focal epithelial hyperplasia, Epidermodysplasia verruciformis, and Plantar cysts. Warts may be transmitted by direct or indirect contact. Events that disrupt the normal epithelial barrier increase the likelihood of developing warts. Treatment may be difficult. Warts often resolve spontaneously within a few years. Some high-risk HPV subtypes are associated with malignancies, including types 6, 11, 16, 18, 31, and 35. Malignant transformation usually is seen in patients with genital warts and immunocompromised patients. HPV types 5, 8, 20, and 47 have oncogenic potential leading to epidermodysplasia verruciformis.
"Common Warts - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Common Warts pipeline landscape is provided which includes the disease overview and Common Warts treatment guidelines. The assessment part of the report embraces, in depth Common Warts commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Common Warts collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Common Warts Emerging Drugs
Mavorixafor: X4 Pharmaceuticals
Mavorixafor as an oral, once-daily treatment for patients with WHIM syndrome. WHIM syndrome is a rare genetic primary immunodeficiency that results from "gain-of-function" mutations in the single gene that encodes for the CXCR4 receptor.
VP-102: Verrica Pharmaceuticals
VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.
Further product details are provided in the report……..
Common Warts: Therapeutic Assessment
This segment of the report provides insights about the Common Warts drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies Common Warts. The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals
DelveInsight's report covers around 5+ products under different phases of clinical development like
Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Common Warts: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Common Warts therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Common Warts drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Common Warts: Overview
Pipeline Therapeutics
Therapeutic Assessment
Common Warts- DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Mavorixafor: X4 Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Diphencyprone: Phio Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Common Warts Key Companies
Common Warts Key Products
Common Warts- Unmet Needs
Common Warts- Market Drivers and Barriers
Common Warts- Future Perspectives and Conclusion
Common Warts Analyst Views
Common Warts Key Companies
Appendix